Physicochemical and preclinical pharmacokinetic and toxicological evaluation of LK-423a new phthalimido-desmuramyl-dipeptide derivative with immunomodulating activity Physicochemical and preclinical evaluation of LK-423

Drug Development and Industrial Pharmacy

Volumn 35, Issue 11, 2009, Pages 1293-1304

  Smrdel, Polona ^a,b   Grabnar, Iztok ^b   Locatelli, Igor ^b   Černe, Manica ^a   Andrenšek, Samo ^a   Kovačič, Nataša ^c   Kristl, Albin ^b   Bogataj, Marija ^b   Urleb, Uroš ^a,b   Mrhar, Aleš ^b  

^a Lek Pharmaceuticals   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c ERICo Velenje   (Slovenia)

Author keywords

Immunomodulating activity; LK 423; Pharmacokinetics; Physicochemical properties; Toxicology

Indexed keywords

DIPEPTIDE DERIVATIVE; IMMUNOMODULATING AGENT; LK 423; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHRONIC TOXICITY; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; IMMUNOMODULATION; MALE; MICROCAPSULE; MOUSE; NONHUMAN; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY; PLASMA CLEARANCE; RAT;

ACUTE TOXICITY TESTS; ADMINISTRATION, ORAL; ANIMALS; CAPSULES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DIPEPTIDES; DOGS; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; IMMUNOLOGIC FACTORS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; INTESTINES; MALE; MASS SPECTROMETRY; MICE; MICE, INBRED STRAINS; MOLECULAR STRUCTURE; PHTHALIMIDES; RATS; RATS, WISTAR; SOLUBILITY; TOXICITY TESTS, CHRONIC;

EID: 70350337362     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040902889814     Document Type: Article

References (26)

1. Kuby J. (1994). Immunology. 2nd ed. New York: Freeman H.W. Co., 297-322.
2. Feldmann M, Brennan M. (2001). Cytokines and diseases. In: Oppenheim JJ, Feldmann M, eds. Cytokine reference, vol.1. London, UK: Academic Press, 35-52.
3. Asadullah K, Sterry W, Volk HD. (2003). Interleukin-10 therapy -review of new approach. Pharmacol Rev, 55:241-269
4. Moore KW, De Waal Malefyt R, Coffman RL, O'Garra A. (2001). Interleukin-10 and the interleukine-10 receptor. Annu Rev Immunol, 19:683-765.
5. Wakkach A, Cottrez F, Groux H. (2000). Can interleukin-10 be used as a true immunoregulatory cytokine? Eur Cytokine Netw, 11:153-160
6. Lindsay JO, Hodgson HJF. (2001). The immunoregulatory cytokine interleukin-10-a therapy for Crohn's disease? Aliment Pharmacol Ther, 15:1709-1716
7. De Waal Malefyt R. (2001). IL-10. In: Oppenheim JJ, Feldmann M, eds. Cytokine reference, vol.1. London, UK: Academic Press, 165-186
8. Ochi C, Norisada N, Moriguchi M, Stalc A, Urleb U, Muraoka S. (1999). Interleukin-10 inducing activity of LK423, a phthalimidodesmuramyldipepdide compound. Arzneimittel-Forschung/ Drug Res, 49:71-79
9. Yoneda F, Muraoka S, Moriguchi M, Norisada N, Ochi C, Stalc A, et al. (2001). Anti-inflammatory medicinal compositions. Patent WO 0135982 A1.
10. Moriguchi M, Urabe K, Norisada N, Ochi C, Stalc A, Urleb U, et al. (1999). Therapeutic effect of LK 423, a phthalimido-desmuramyldipeptide compound, on dextran sulfate sodium-induced colitis in rodents through restoring their interleukin-10 producing capacity. Arzneimittel-Forschung/Drug Res, 49:184-192
11. Urleb U, Krbavčič A, Sollner M, Kikelj D, Pečar S. (1995). Synthesis of phthalimido-desmuramylpeptide analogues as potential immunomodulating agents. Arch Pharm, 328:113-117
12. Albert A, Serjeant EP. (1984). The determination of ionization constants: A laboratory manual. 3rd ed. New York: Chapman and Hall, 56-60.
13. Bogataj M, Mrhar A, Lavri1 A, Cerne M, Tibaud D, Štalc A, et al. (2005). Gastroresistant pharmaceutical dosage form comprising N-(2-(2-phthalimidoethoxy-)acetyl)-L-alanyl-D-glutamic acid (LK-423). Patent WO 2005/092295 A1.
14. Smrdel P, Bogataj M, Zega A, Planinšek O, Mrhar A. (2008). Shape optimization and characterization of polysaccharide beads prepared by ionotropic gelation. J Microencapsul, 25:90-105. (Pubitemid 351233915)
15. Legen I, Kristl A. (2003). pH and energy dependent transport of ketoprofen across rat jejunum in vitro. Eur J Pharm Biopharm, 56:87-94.
16. Van Dongen JJ, Remie R, Rensema JW, Van Wunnik GHJ. (1998). Manual of microsurgery on the laboratory rat. Part I. Amsterdam, The Netherlands: Elsevier science B.V.
17. Tuleu C, Andrieux C, Boy P, Chaumeil JC. (1999). Gastrointestinal transit of pellets: Effect of size and density. Int J Pharm, 180:123-131
18. De Zwart LL, Rompelberg CJM, Sips AJAM, Welink J, Van Engelen JGM. (1999). Anatomical and physiological differences between various species used in studies on the pharmacokinetics and toxicology of xenobiotics. RIVM report 623860010. Bilthoven, The Netherlands: RIVM.
19. Kararli TT. (1995). Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos, 16:351-380
20. Rubio-Aliga I, Hannelore D. (2002). Mammalians peptide transporters as targets for drug delivery. Trends Pharmacol Sci, 23:434-440
21. Walter E, Kissel T, Amidon LG. (1996). The intestinal peptide carrier: A potential transport system for small peptide derived drugs. Adv Drug Deliv Rev, 20:33-58.
22. Norinder U, Haeberlein M. (2003). Calculated molecular properties and multivariate statistical analysis in absorption prediction. In: Van de Waterbeemd FH, Lennernäs H, Artursson P, eds. Drug bioavailability: Estimation of solubility, permeability, absorption and bioavailability, vol.18. Weinheim, Germany: Wiley-VCH Verlag, 358-405.
23. Rinaki E, Valsami G, Macheras P. (2003). Quantitative biopharmaceutics classification system: The central role of dose/ solubility ratio. Pharm Res, 20:1917-1925
24. He YL, Murby S, Warhurst G, Gifford L, Walker D, Ayrton J, et al. (1998). Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. J Pharm Sci, 87:626-633
25. Herfarth H, Schölmerich J. (2002). IL-10 therapy in Crohn's disease: At the crossroads. Gut, 50:146-147
26. Steidler L, Hans W, Schotte L, Neirynck S, Obermeir F, Falk W, et al. (2000). Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science, 289:1352-1355